Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Sci Rep ; 3: 2960, 2013 Oct 16.
Artigo em Inglês | MEDLINE | ID: mdl-24129891

RESUMO

Interleukin (IL)-32 is known to exert adujvant effects on innate immune response, however, receptors and downstream signaling pathways remain to be clarified. Here we found that IL-32γ upregulated serine protease activity of proteinase-3 (PR3), in turn triggering protease-activated receptor 2 (PAR2) signaling. Interestingly, silencing of PR3 or PAR2 using siRNA markedly diminished IL-32γ-induced TNFα and IFN-ß mRNA expression. IL-32γ-PAR2 axis utilized TRIF and Ras-Raf-1 pathways. On stimulation with lipopolysaccharide (LPS), differential activation of protein kinase C isoforms modulated the balance between LPS-TLR4-TRIF and IL-32-PAR2-TRIF axes, because LPS was a strong inducer of IL-32γ. IL-32-PAR2-TRIF axis might serve not only as an extracellular sensor of bacterial and autologous proteases, but also as a modulator of innate and adaptive immunity during infection.


Assuntos
Proteínas Adaptadoras de Transporte Vesicular/metabolismo , Imunidade Inata/fisiologia , Interleucinas/metabolismo , Lipopolissacarídeos/metabolismo , Receptor PAR-2/metabolismo , Transdução de Sinais , Regulação da Expressão Gênica , Humanos , Interferon beta/biossíntese , Interferon beta/genética , Interleucinas/imunologia , Lipopolissacarídeos/imunologia , Modelos Biológicos , Proteína Quinase C/metabolismo , Proteínas Proto-Oncogênicas c-raf/metabolismo , Proteínas Proto-Oncogênicas p21(ras)/metabolismo , Receptores Toll-Like/metabolismo , Fator de Necrose Tumoral alfa/antagonistas & inibidores , Fator de Necrose Tumoral alfa/biossíntese , Fator de Necrose Tumoral alfa/genética
2.
Orthopedics ; 35(9): e1438-41, 2012 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-22955416

RESUMO

This article describes 2 cases of osteochondroma emanating from the posterior aspect of the femoral neck with a fracture at the base of its stalk caused by impingement between the tumor and the ischium. A 44-year-old man and a 57-year-old man presented with left hip pain. Radiographs revealed a mass at the posterior aspect of the femoral neck. Computed tomography and magnetic resonance imaging revealed that the mass was fractured at the stalk. The relationship between the tumor and the ischium was examined with an image intensifier. The tumor impinged on the ischium with slight flexion and external rotation of the hip joint. In both patients, the tumor was excised, and the pathological report was osteochondroma. At follow-up, the patients had full hip joint range of motion, and lateral radiographs of the left hip joint showed complete resection of the tumor without recurrence. To the authors' knowledge, the current cases are the first reports of fracture of an osteochondroma with confirmed impingement using an image intensifier pre- and intraoperatively. Both patients had histories of restricted hip range of motion and a sudden onset of pain. After excision, the patients recovered to activities of daily living with no complications. An osteochondroma at the posterior aspect of the femoral neck can impinge on the ischium and fracture at its base with a sudden onset of pain. Awareness of this mechanism of impingement may lead to a better understanding of patient symptoms caused by osteochondroma of the femoral neck.


Assuntos
Neoplasias Ósseas/complicações , Neoplasias Ósseas/cirurgia , Fraturas do Colo Femoral/etiologia , Fraturas do Colo Femoral/cirurgia , Ísquio/cirurgia , Osteocondroma/complicações , Osteocondroma/cirurgia , Adulto , Neoplasias Ósseas/diagnóstico , Fraturas do Colo Femoral/diagnóstico , Humanos , Ísquio/diagnóstico por imagem , Masculino , Pessoa de Meia-Idade , Osteocondroma/diagnóstico , Radiografia , Resultado do Tratamento
3.
Arthritis Res Ther ; 14(3): R120, 2012 May 21.
Artigo em Inglês | MEDLINE | ID: mdl-22613074

RESUMO

INTRODUCTION: The present study assessed the potential functions of interleukin (IL)-32α on inflammatory arthritis and endotoxin shock models using IL-32α transgenic (Tg) mice. The potential signaling pathway for the IL-32-tumor necrosis factor (TNF)α axis was analyzed in vitro. METHODS: IL-32α Tg mice were generated under control of a ubiquitous promoter. Two disease models were used to examine in vivo effects of overexpressed IL-32α: Toll-like receptor (TLR) ligand-induced arthritis developed using a single injection of lipopolysaccharide (LPS) or zymosan into the knee joints; and endotoxin shock induced with intraperitoneal injection of LPS and D-galactosamine. TNFα antagonist etanercept was administered simultaneously with LPS in some mice. Using RAW264.7 cells, in vitro effects of exogenous IL-32α on TNFα, IL-6 or macrophage inflammatory protein 2 (MIP-2) production were assessed with or without inhibitors for nuclear factor kappa B (NFκB) or mitogen-activated protein kinase (MAPK). RESULTS: Single injection of LPS, but not zymosan, resulted in development of severe synovitis with substantial articular cartilage degradation in knees of the Tg mice. The expression of TNFα mRNA in inflamed synovia was highly upregulated in the LPS-injected Tg mice. Moreover, the Tg mice were more susceptive to endotoxin-induced lethality than the wild-type control mice 48 hours after LPS challenge; but blockade of TNFα by etanercept protected from endotoxin lethality. In cultured bone marrow cells derived from the Tg mice, overexpressed IL-32α accelerated production of TNFα upon stimulation with LPS. Of note, exogenously added IL-32α alone stimulated RAW264.7 cells to express TNFα, IL-6, and MIP-2 mRNAs. Particularly, IL-32α -induced TNFα, but not IL-6 or MIP-2, was inhibited by dehydroxymethylepoxyquinomicin (DHMEQ) and U0126, which are specific inhibitors of nuclear factor kappa B (NFκB) and extracellular signal regulated kinase1/2 (ERK1/2), respectively. CONCLUSIONS: These results show that IL-32α contributed to the development of inflammatory arthritis and endotoxin lethality. Stimulation of TLR signaling with LPS appeared indispensable for activating the IL-32α-TNFα axis in vivo. However, IL-32α alone induced TNFα production in RAW264.7 cells through phosphorylation of inhibitor kappa B (IκB) and ERK1/2 MAPK. Further studies on the potential involvement of IL-32α-TNFα axis will be beneficial in better understanding the pathology of autoimmune-related arthritis and infectious immunity.


Assuntos
Artrite Experimental/metabolismo , Interleucinas/metabolismo , Choque Séptico/metabolismo , Transdução de Sinais/fisiologia , Fator de Necrose Tumoral alfa/biossíntese , Animais , Artrite Experimental/genética , Artrite Experimental/patologia , Humanos , Immunoblotting , Interleucinas/genética , Lipopolissacarídeos/imunologia , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Transgênicos , Reação em Cadeia da Polimerase em Tempo Real , Choque Séptico/genética , Choque Séptico/patologia
4.
Biomaterials ; 31(6): 1191-8, 2010 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-19913294

RESUMO

Development of bone morphogenetic protein (BMP) signaling modulators may provide useful therapeutic options for the treatment of large bony defects in clinical settings. Controversy remains over whether hepatocyte growth factor (HGF) is a positive or negative modulator of BMP-induced osteogenesis. This study analyzed osteogenic properties of HGF, particularly during BMP-2-induced bone formation. Using a mouse model of ectopic bone formation, HGF-impregnated gelatin sponges displayed significantly reduced bone formation induced by BMP-2, both radiologically and histologically. Abrogation of endogenous HGF production by knockdown of HGF mRNA resulted in upregulation of BMP-2-induced ALP activity for C2C12 myoblasts in vitro. In contrast, addition of exogenous HGF inhibited BMP-2-induced ALP activity and osteocalcin production by mouse embryonic fibroblasts (MEFs) through HGF-c-Met interactions. Inhibition of ALP activity by HGF was rescued by U0126, a MEK1/2 inhibitor, indicating that HGF suppresses the BMP-2-Smad axis via activation of ERK1/2. Importantly, treatment with HGF prior to administration of BMP-2 induced cellular proliferation of MEFs and did not influence subsequent osteoblast differentiation induced by BMP-2. The effects of HGF may differ according to the differentiation stage of mesenchymal stem cells, which would explain the inconsistencies seen in osteogenic properties of HGF in previous reports. The timing of HGF treatment is critical and should be carefully determined for successful induction of bone formation by BMPs.


Assuntos
Proteína Morfogenética Óssea 2/administração & dosagem , Fator de Crescimento de Hepatócito/administração & dosagem , Mioblastos/citologia , Mioblastos/efeitos dos fármacos , Osteoblastos/citologia , Osteoblastos/efeitos dos fármacos , Osteogênese/efeitos dos fármacos , Animais , Diferenciação Celular/efeitos dos fármacos , Linhagem Celular , Sinergismo Farmacológico , Camundongos , Osteogênese/fisiologia , Fatores de Tempo , Engenharia Tecidual/métodos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...